CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Dr Phillips on the Management of Toxicities Associated With CAR T-Cell Therapy

November 21st 2023

Adrienne Phillips, MD, MPH, discusses the management of toxicities associated with CAR T-cell therapy across hematologic malignancies.

Dr Hasan on the Preclinical Efficacy of ROR1-Specific CAR T-Cells in CLL

November 20th 2023

Md Kamrul Hasan, PhD, discusses the preclinical efficacy and safety of ROR1-specific CAR T-cells in a preclinical mouse model of chronic lymphocytic leukemia.

FDA’s ODAC to Review Data for Ide-Cel in Triple-Class Exposed R/R Myeloma

November 20th 2023

The FDA’s Oncologic Drugs Advisory Committee will meet to review data from the supplemental biologics license application seeking the approval of idecabtagene vicleucel for use in earlier lines of treatment for patients with triple-class exposed relapsed/refractory multiple myeloma.

CAR-M Therapy CT-0508 Shows Promise in HER2-Overexpressing Recurrent/Metastatic Solid Tumors

November 19th 2023

The HER2-directed CAR-macrophage therapy CT-0508 displayed a tolerable safety profile and signs of antitumor activity in patients with a variety of solid tumors.

Research Aims to Make Inroads With CAR T-Cell Therapy in Advanced RCC

November 11th 2023

Although not immediately practice changing, CAR T-cell therapy has the potential to become a standard of care for patients with advanced renal cell carcinoma following progression on checkpoint inhibitors and VEGF inhibitors.

Dr Leick on Limitations Associated With CAR T-Cell Therapy in Hematologic Malignancies

November 9th 2023

Mark Leick, MD, discusses the challenges and limitations associated with the use of CAR T-cell therapy across hematologic malignancies, highlighting how ongoing research may potentially ameliorate present unmet needs.

FDA Grants Priority Review to Liso-Cel for R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

November 9th 2023

The FDA has granted priority review to the supplemental biologics license application seeking approval to expand the indication of lisocabtagene maraleucel to include patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had prior exposure to a BTK inhibitor and a BCL-2 inhibitor.

Dr Leick on the Use of CAR T-Cell Therapy Across Hematologic Malignancies

November 7th 2023

Mark Leick, MD, discusses the varying role of CAR T-cell therapy across various hematologic malignancies, elaborating on the cause of its effectiveness in these disease spaces.

Research Remains Focused on Bringing CAR T-Cell Therapy to Solid Tumors

November 7th 2023

Mark Leick, MD, discusses how the emergence of CAR T-cell therapies have affected the treatment paradigms in various hematologic malignancies, expands on how persisting challenges with the use of this type of treatment are being addressed, and details research into the use of CAR T-cell therapy in patients with solid tumors.

FDA Accepts IND for Novel CDH17-Targeted CAR T-Cell Therapy for Advanced Gastrointestinal Cancers

November 6th 2023

The FDA has cleared the investigational new drug application for CHM 2101, a novel CDH17-targeted CAR T-cell therapy, for the treatment of patients with gastrointestinal cancers.

BNT211 With or Without CARVac Shows Early Activity in CLDN6+ R/R Advanced Solid Tumors

November 5th 2023

The Claudin-6–directed CAR T-cell therapy, BNT211, showed signs of clinical activity in patients with CLDN6-positive relapsed or refractory solid tumors.

Dr Murthy on the Use of CAR T-Cell Therapy in Elderly or Frail Patients With B-Cell Lymphomas

October 30th 2023

Hemant S. Murthy, MD, discusses the evolving use of CAR T-cell therapy for elderly or frail patients with relapsed/refractory B-cell lymphomas.

Strategies to Improve Manufacturing Time, Mitigate Toxicities of CAR T-Cell Therapy Remain a Focus in R/R LBCL

October 12th 2023

Hemant S. Murthy, MD, emphasizes the importance of an accelerated manufacturing process for CAR T-cell therapy, discusses the use of CAR T-cell therapy in older and frail patients, and highlights toxicity management strategies that have implemented and are under evaluation for patients receiving CAR T-cell therapy.

Dr Nastoupil on the Background of the TRANSCEND FL Trial in Follicular Lymphoma

September 28th 2023

Loretta J. Nastoupil, MD, discusses the rationale for launching the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma, highlighting the background for investigating this treatment approach.

Dr Hecht on Barriers to Enrollment into the BASECAMP-1 Study in Solid Tumors

September 26th 2023

J. Randolph (Randy) Hecht, MD, discusses barriers to enrollment in the observational BASECAMP-1 study and the phase 1/2 EVEREST-1 study, which will investigate HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in patients with solid tumors.

Dr Qin on the Use of CAR T-Cell Therapy in ccRCC

September 26th 2023

Qian (Janie) Qin, MD, discusses the investigation and use of CAR T-cell therapy in patients with advanced clear cell renal cell carcinoma.

Dr. Disis on the Rationale For Investigating PRGN-3005 With/Without Lymphodepletion in Ovarian Cancer

September 26th 2023

Mary “Nora” Disis, MD, discusses the rationale for investigating the efficacy and optimal delivery of PRGN-3005 autologous UltraCAR T cells in patients with advanced stage platinum-resistant ovarian cancer.

Dr Hecht on the Investigation of the Novel CAR T-Cell Therapy A2B530 in Solid Tumors

September 25th 2023

J. Randolph (Randy) Hecht, MD, discusses the observational BASECAMP-1 study and the investigation of HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in the phase 1/2 EVEREST-1 study, which will investigate A2B530 in patients with solid tumors.

Dr Hecht on Barriers to CAR T-Cell Therapy Treatment in Solid Tumors

September 22nd 2023

J. Randolph (Randy) Hecht, MD, discusses barriers to treatment with CAR T-cell therapy in patients with solid tumors, highlighting various efforts that investigators are spearheading to address these unmet needs.

Novel Targets Could Expand CAR T-Cell Therapy and Bispecific Antibody Options in Myeloma

September 22nd 2023

Ajai Chari, MD, discusses selecting between CAR T-cell therapies and bispecific antibodies in multiple myeloma, expands on the factors that can help inform these decisions, and highlights the need for additional data to help inform sequencing and potential combinations for these therapies.